C9084 — Injection, loncastuximab tesirine-lpyl, 0.1 mg
C9084 is a HCPCS Level II code for injection, loncastuximab tesirine-lpyl, 0.1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on March 31, 2022 and is not valid on new claims.
This code has been terminated
CMS terminated C9084 on March 31, 2022. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9084
- Long descriptor
- Injection, loncastuximab tesirine-lpyl, 0.1 mg
- Short descriptor
- Loncastuximab-lpyl, 0.1 mg
- Added
- October 1, 2021
- Terminated
- March 31, 2022
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9084
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9084 is not quite right, the correct code is very often within a few positions of it.
- C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9077Injection, cabotegravir and rilpivirine, 2mg/3mgterminated
- C9078Injection, trilaciclib, 1 mgterminated
- C9079Injection, evinacumab-dgnb, 5 mgterminated
- C9080Injection, melphalan flufenamide hydrochloride, 1 mgterminated
- C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9082Injection, dostarlimab-gxly, 100 mgterminated
- C9083Injection, amivantamab-vmjw, 10 mgterminated
- C9085Injection, avalglucosidase alfa-ngpt, 4 mgterminated
- C9086Injection, anifrolumab-fnia, 1 mgterminated
- C9087Injection, cyclophosphamide, (auromedics), 10 mgterminated
- C9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mgterminated
- C9089Bupivacaine, collagen-matrix implant, 1 mgterminated
- C9090Injection, plasminogen, human-tvmh, 1 mgterminated
- C9091Injection, sirolimus protein-bound particles, 1 mgterminated
- C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgterminated
Questions about C9084
What is HCPCS code C9084?
C9084 is a HCPCS Level II code for injection, loncastuximab tesirine-lpyl, 0.1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9084?
The CMS HCPCS file marks C9084 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9084 still valid?
No. C9084 was terminated on March 31, 2022 and should not be used on new claims.